Aspira Women's Health 2023 rev $9.2M (+15% YoY); cash burn halved to $15.9M

Aspira Women's Health Inc.

Q4 product revenue $2.1M flat YoY; OvaSuite volume ~5,659 tests.
Full year 2023 OvaSuite volume 23,990 units (+12% YoY); AUP $382.
Cash used in operations $15.9M for 2023, down 49% from $31.1M in 2022.
Gross margin improved to 57.5% from 52.8% on lower lab/shipping costs.
Raised $5.5M in registered direct offering post year-end; cash $2.9M at Dec 31.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Aspira Women's Health Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue Product revenue was $2.1 million for the three months ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Revenue: Product revenue was $2.1 million for the three months ended December 31, 2023
Result: reported results

Exact text from the filing

Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.